Ascendiant Capital Markets Forecasts Strong Price Appreciation for Aemetis (NASDAQ:AMTX) Stock

Aemetis (NASDAQ:AMTX - Get Free Report) had its price target raised by investment analysts at Ascendiant Capital Markets from $19.00 to $20.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the specialty chemicals company's stock.

AMTX has been the topic of a number of other reports. UBS Group dropped their price objective on shares of Aemetis from $2.50 to $2.20 and set a "buy" rating on the stock in a report on Friday, May 9th. HC Wainwright reiterated a "buy" rating and set a $28.00 price target on shares of Aemetis in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $13.43.

Aemetis Price Performance

Aemetis stock traded up $0.23 during midday trading on Friday, reaching $1.95. The company's stock had a trading volume of 2,052,393 shares, compared to its average volume of 751,599. The stock has a market capitalization of $107.97 million, a P/E ratio of -0.86 and a beta of 1.47. The stock's 50-day simple moving average is $1.55 and its 200-day simple moving average is $2.18. Aemetis has a 52-week low of $1.22 and a 52-week high of $4.73.

Aemetis (NASDAQ:AMTX - Get Free Report) last released its earnings results on Thursday, May 8th. The specialty chemicals company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.08). The company had revenue of $42.89 million for the quarter, compared to the consensus estimate of $59.35 million. During the same period in the previous year, the business earned ($0.58) EPS. As a group, equities research analysts expect that Aemetis will post -2.07 earnings per share for the current fiscal year.

Institutional Trading of Aemetis

Hedge funds and other institutional investors have recently made changes to their positions in the business. ProShare Advisors LLC acquired a new stake in Aemetis during the 4th quarter worth about $27,000. Tower Research Capital LLC TRC boosted its stake in shares of Aemetis by 128.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company's stock worth $28,000 after buying an additional 5,859 shares during the last quarter. Voya Investment Management LLC acquired a new stake in Aemetis during the fourth quarter worth about $28,000. Intech Investment Management LLC acquired a new stake in Aemetis during the fourth quarter worth about $46,000. Finally, SG Americas Securities LLC purchased a new position in Aemetis during the fourth quarter valued at approximately $87,000. Institutional investors and hedge funds own 27.02% of the company's stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.